

Electronic Acknowledgement Receipt

EFS ID:	6002767
Application Number:	10585772
International Application Number:	
Confirmation Number:	4680
Title of Invention:	Antisense Oligonucleotides Directed to Ribonucleotide Reductase R2 and Uses Thereof in Combination Therapies for the Treatment of Cancer
First Named Inventor/Applicant Name:	Aiping H. Young
Customer Number:	21559
Filer:	Forrester J. Liddle/Terese Miffitt
Filer Authorized By:	Forrester J. Liddle
Attorney Docket Number:	50120/008001
Receipt Date:	02-SEP-2009
Filing Date:	13-NOV-2007
Time Stamp:	15:53:55
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 245
RAM confirmation Number	2227
Deposit Account	032095
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		50120_008001_Reply_OA.PDF	1159995 f97ce7f9e00f2698527f8e2b5d126122f5f2f255	yes	19
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment/Req. Reconsideration-After Non-Final Reject		1	1	
	Claims		2	7	
	Applicant Arguments/Remarks Made in an Amendment		8	19	
Warnings:					
Information:					
2	Oath or Declaration filed	50120_008001_Declaration.PDF	84331 65ebb5070d0e1b69d321a386c9cecb07a37cf856	no	2
Warnings:					
Information:					
3	Extension of Time	50120_008001_Petition_Extension.PDF	120247 59772c8dd0fad8fff26bb3e2d0ff0bb9704203d4	no	1
Warnings:					
Information:					
4	Fee Worksheet (PTO-875)	fee-info.pdf	30475 9c2bb1d2b0ed5efd60dd418d4ef787e163a7d162	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			1395048		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.